Our skin acts as an important barrier to prevent infection and is a dynamic organ with a vital function. Diseases of the skin are found in all age groups and include many different conditions.
Some of the most common skin diseases are eczema, psoriasis, acne and skin cancer. Some of Meda’s biggest products are in the dermatology therapy area:
Betadine (treatment and prevention of infections in the skin and mucous membranes caused by bacteria, fungi, and viruses) and Aldara (treatment of actinic keratosis, superficial basal cell carcinomas, and external genital warts), and Elidel (treatment of atopic eczema).
Other Meda products in the dermatology therapy area include Solcoseryl (for wound care), Dermatix (a topical silicone gel that helps to maintain moisture balance in the skin, which for example, reduces scar formation), Efudix (a topical treatment for superficial pre malignant and malignant skin lesions), and Kamillosan (a chamomile concentrate for treatment of minor wounds and inflammation in the skin and mucous membrane
Key Products in Dermatology
Aldara has three indications: actinic keratosis, superficial basal cell carcinomas,and external genital warts in men and women.
The active ingredient in Aldara is imiquimod, a proprietary ingredient with a unique action mechanism. Imiquimod is an immunomodulating agent that activates the body's own immune defenses through the skin.
- Actinic keratosis is a skin disease characterized by reddish-brown, flaky spots on sun-damaged skin; the condition is precancerous, and could lead to squamous cell carcinoma.
- Superficial basal cell carcinoma is the most common type of skin cancer and can be caused by sun exposure. Aldara works with the body’s immune system to form natural substances that help fight superficial basal cell carcinoma or combat the virus that causes changes in the skin. Since superficial basal cell carcinoma is rarely metastatic, most patients can be cured.
- External genital warts in men and women are caused by the human papilloma virus.
Elidel is a proprietary drug for the treatment of atopic eczema based on pimecrolimus. Atopic eczema is a chronic, recurring inflammatory skin disease. The skin has a barrier function that plays a key role in defense against atopic eczema flare-ups.
Elidel is the first topical preparation developed for the treatment of atopic eczema that does not contain a corticosteroid. Elidel has been documented in studies involving more than 60,000 patients. Elidel is currently available for sale in 90 markets around the world, through Meda’s own marketing organization and through partners. In North America, Elidel is out-licensed to Valeant, who will also partner with Meda for product development related to Elidel.
Zyclara can be used to treat actinic keratosis. The active ingredient in Zyclara is imiquimod 3.75%, with a unique formulation that means that Zyclara can be used on a significantly larger treatment area. Zyclara was approved in Europe in 2012 and the product is due to be launched in 2013.